Capecitabine 500mg Tablet, Film Coated
Product Images NDC 72485-205

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine 500mg (NDC 72485-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72485205 2

Label for Capecitabine Tablets, USP 500 mg by Armas Pharmaceuticals Inc. The film-coated oral tablets are cytotoxic agents supplied in a package of 120 tablets. The label includes dosage form, strength, storage instructions, and manufacturer and distributor details, along with a barcode and a caution to swallow tablets whole without crushing or cutting.*

FDA Label Image

Figure 1 Kaplan-meier Estimates Of Disease-free Survival (all Randomized Population)a (Fig 1)

A survival curve chart comparing two treatment groups over time post-randomization: one receiving 5-FU plus Leucovorin (dashed line) and the other receiving Capecitabine (solid line). The x-axis represents months since randomization, and the y-axis shows survival probability from 0 to 1. The number at risk for each group is displayed below the x-axis at various time points.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Overall Survival (all Randomized Population) (Fig 2)

A survival curve chart comparing two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line). The x-axis represents months since randomization (0 to 108), and the y-axis shows survival probability (0.3 to 1.0). The chart includes patient numbers at risk for each group over time.*

FDA Label Image

Figure 3 Kaplan-meier Curve For Overall Survival Of Pooled Data (studies 1 And 2) (Fig 3)

A Kaplan-Meier survival curve comparing estimated probabilities over time (days) for two treatment groups: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent. The chart shows survival probability on the vertical axis and time in days on the horizontal axis, with survival decreasing over approximately 1500 days.*

FDA Label Image

Figure 4 Kaplan-meier Estimates For Time To Disease Progression Capecitabine And Docetaxel Vs Docetaxel (Fig 4)

A Kaplan-Meier survival curve comparing two treatment groups over time in days. One group received Docetaxel 100 mg/sqm every 3 weeks, depicted with a dashed line. The other group received Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks, shown with a solid line. The y-axis shows estimated probability from 0 to 1.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Survival Capecitabine And Docetaxel Vs Docetaxel (Fig 5)

A line graph showing estimated probability over time (days) comparing two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks (solid line). The x-axis represents time in days, and the y-axis represents estimated probability.*

FDA Label Image

Metabolic Pathway (Meta Pathway)

A chemical reaction diagram showing the enzymatic conversion of Capecitabine to 5-FU. It includes labeled molecular structures for Capecitabine, 5'-DFCR, 5'-DFUR, and 5-FU, with arrows indicating conversions mediated by Carboxylesterase, Cyd deaminase, and dThdPase enzymes.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure diagram of the active ingredient Capecitabine. The structural formula shows the molecular arrangement including carbon, hydrogen, nitrogen, oxygen, and fluorine atoms represented by standard chemical notation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.